Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
According to a media release issued on Thursday by IRIS International, the U.S. Food & Drug Administration (FDA) has approved the company’s NADiA® ProsVue™ test as a prognostic marker that can “aid in identifying” men at reduced risk for recurrence of prostate cancer in the first 8 years after a prostatectomy.
Filed under: Living with Prostate Cancer, Management, Uncategorized | Tagged: NADiA, prognosis, progression, ProsVue, radical prostatectomy | Leave a Comment »
IRIS Molecular Diagnostics has submitted an application to the U.S. Food and Drug Administration to market a prostate cancer prognostic test called NADiA® ProsVue™. The company says that this test is “designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.”
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: NADiA, prognosis, ProsVue, radical prostatectomy | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site